ECTRIMS eLearning

T and B lymphocyte subsets of anti myelin oligodendrocyte glycoprotein-related disorder and anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder in remission
Author(s): ,
S Tanaka
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
A Kubota
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
M Kojima
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
S Izaki
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
T Dembo
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
H Fukaura
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
,
K Kaneko
Affiliations:
Tohoku University, Sendai, Japan
,
D.K Sato
Affiliations:
Tohoku University, Sendai, Japan
,
I Nakashima
Affiliations:
Tohoku University, Sendai, Japan
K Nomura
Affiliations:
Neurology, Saitama Medical Center, Kawagoe
ECTRIMS Learn. Tanaka S. 09/15/16; 146279; P439
Satoru Tanaka
Satoru Tanaka
Contributions
Abstract

Abstract: P439

Type: Poster

Abstract Category: Pathology and pathogenesis of MS - Immunology

Objective: We study the subsets of T and B lymphocytes present in the active and remission phases of anti-myelin oligodendrocyte glycoprotein (MOG)-related disorder (MOG-RD) and anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). In this study, the subsets of

T and B cells in peripheral blood were compared in patients in remission.

Patients and methods: Peripheral blood was collected from 5 and 12 patients who had been treated for acute MOG-RD and AQP4-NMOSD, respectively, ≥1 month earlier and were presently in remission. The levels of anti-MOG and anti-AQP4 antibodies was measured by the Department of Neurology, Tohoku University School of Medicine. Without removing red blood cells, 2 ml peripheral blood was subjected to staining of various T- and B-cell surface markers and flow cytometry using BD FACSCanto II (Becton, Dickinson and Company). T cells examined in this study were CD8+ CD11b cytotoxic T cells, activated CD4 (CD4+ HLA+) T cells, activated CD8 (CD8+ HLA+) T cells, CD4+ CD25high regulatory T cells, and CD3 CD16/56+ natural killer cells. B cells examined were CD19+ CD27+ CD38high CD180 plasmablasts, CD19+ CD27+ memory B cells, CD19+ CD27 naive B cells, and CD19+ CD24high CD38high transitional B cells.

Results: No significant difference in T cell subsets was observed between the two disorders. As for B cell subsets, the level of plasmablasts was significantly higher in patients with AQP4-NMOSD (1.9±1.72) than in those with MOG-RD (0.74±0.62), whereas no significant difference was observed in transitional, naive, and memory B cells.

Conclusion: Plasmablasts might be involved in the pathology of AQP4-NMOSD, but not MOG-RD, even in the remission phase.

Disclosure: nothing

Abstract: P439

Type: Poster

Abstract Category: Pathology and pathogenesis of MS - Immunology

Objective: We study the subsets of T and B lymphocytes present in the active and remission phases of anti-myelin oligodendrocyte glycoprotein (MOG)-related disorder (MOG-RD) and anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). In this study, the subsets of

T and B cells in peripheral blood were compared in patients in remission.

Patients and methods: Peripheral blood was collected from 5 and 12 patients who had been treated for acute MOG-RD and AQP4-NMOSD, respectively, ≥1 month earlier and were presently in remission. The levels of anti-MOG and anti-AQP4 antibodies was measured by the Department of Neurology, Tohoku University School of Medicine. Without removing red blood cells, 2 ml peripheral blood was subjected to staining of various T- and B-cell surface markers and flow cytometry using BD FACSCanto II (Becton, Dickinson and Company). T cells examined in this study were CD8+ CD11b cytotoxic T cells, activated CD4 (CD4+ HLA+) T cells, activated CD8 (CD8+ HLA+) T cells, CD4+ CD25high regulatory T cells, and CD3 CD16/56+ natural killer cells. B cells examined were CD19+ CD27+ CD38high CD180 plasmablasts, CD19+ CD27+ memory B cells, CD19+ CD27 naive B cells, and CD19+ CD24high CD38high transitional B cells.

Results: No significant difference in T cell subsets was observed between the two disorders. As for B cell subsets, the level of plasmablasts was significantly higher in patients with AQP4-NMOSD (1.9±1.72) than in those with MOG-RD (0.74±0.62), whereas no significant difference was observed in transitional, naive, and memory B cells.

Conclusion: Plasmablasts might be involved in the pathology of AQP4-NMOSD, but not MOG-RD, even in the remission phase.

Disclosure: nothing

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies